Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;132(10):863-865.
doi: 10.1038/s41416-025-03026-0. Epub 2025 Apr 18.

Soluble VE-cadherin as a biomarker of response to immunotherapy by anti-PD1 in metastatic melanoma

Clémentine Broche #  1 , Khémary Um #  2   3 , Isabelle Vilgrain  4 , Stéphane Mouret  1   5 , Marie-Thérèse Leccia  1   2 , Arnaud Seigneurin  6   7 , Laurence Bouillet  8 , Marie Enquebecq  1 , Aude Salomon  9 , Caroline Aspord  2   3 , Benoit Busser  5   10 , Pauline Porret  11 , Aude Belbezier  12   13 , Laurence Chaperot  2   3 , Julie Charles  1   2
Affiliations

Soluble VE-cadherin as a biomarker of response to immunotherapy by anti-PD1 in metastatic melanoma

Clémentine Broche et al. Br J Cancer. 2025 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing financial interests in relation to the work described. S. Vilgrain has filed a patent related to sVE-cadherin dosage https://patents.google.com/patent/US20100120171A1/en . Ethical approval: Reviewed and approved by local medical ethics committee. Ethics approval and consent to participate: The study was conducted in accordance with the Declaration of Helsinki. All procedures were approved by the Ethics Committee of Grenoble University Hospital and declared under the reference #DC-2008-787. All participants signed informed consent forms. Consent for publication: No individual person’s data in any form is included in this article.

References

    1. Schörghofer D, Vock L, Mirea MA, Eckel O, Gschwendtner A, Neesen J, et al. Late stage melanoma is hallmarked by low NLGN4X expression leading to HIF1A accumulation. Br J Cancer. 2024;131:468–80. - PMC - PubMed
    1. Oraiopoulou M-E, Couturier D-L, Bunce EV, Cannell IG, Sweeney PW, Naylor H, et al. The in vitro dynamics of pseudo-vascular network formation. Br J Cancer. 2024;131:457–67. - PMC - PubMed
    1. Fucà G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S, et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer. 2020;123:403–9. - PMC - PubMed
    1. Mesti T, Grašič Kuhar C, Ocvirk J. Biomarkers for outcome in metastatic melanoma in first-line treatment with immune checkpoint inhibitors. Biomedicines. 2023;11:749. - PMC - PubMed
    1. Ou Y, Liang S, Gao Q, Shang Y, Liang J, Zhang W, et al. Prognostic value of inflammatory markers NLR, PLR, LMR, dNLR, ANC in melanoma patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review. Front Immunol. 2024. 10.3389/fimmu.2024.1482746. - PMC - PubMed

LinkOut - more resources